Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women

Area of Science:

• Reproductive Endocrinology
• Menopause Management
• Pharmacology

Background:

• Previous hormone replacement therapy (HRT) efficacy studies predominantly involved Caucasian women in Europe, North America, and Australia, with short study durations (≤6 months).
• Limited research exists on HRT's long-term effects and acceptance among diverse ethnic populations, particularly Middle-Eastern women experiencing menopausal symptoms.

Purpose of the Study:

• To evaluate the 12-month efficacy and safety of two distinct HRT regimens in Middle-Eastern postmenopausal women.
• To assess the impact of HRT on a range of short- and intermediate-term menopausal symptoms.

Main Methods:

• A 12-month prospective study enrolled 100 healthy Libyan women with postmenopausal symptoms.
• Participants were randomized to receive either continuous tibolone 2.5 mg or continuous 17beta-oestradiol/dydrogesterone (2/10 mg) oral tablets.
• Menopausal symptoms (hot flushes, night sweats, insomnia, etc.) were assessed at baseline and at 3, 6, and 12 months.

Main Results:

• Both HRT groups showed significant symptom improvement within 3 months, with complete symptom relief by 6 months.
• Symptom improvements were sustained over the entire 12-month study period.
• High acceptance rates for both tibolone and 17beta-oestradiol/dydrogesterone regimens were observed.

Conclusions:

• Tibolone and 17beta-oestradiol/dydrogesterone are effective and safe for treating menopausal symptoms in Middle-Eastern women within 6 months.
• No significant differences were found between the two HRT regimens in terms of efficacy or safety.
• HRT is highly recommended for managing menopausal symptoms in this population, based on the study's findings.